Abstract
Tobacco smoking is the most important preventable cause of cardiovascular disease. In this paper we review current epidemiological and pathophysiological evidence linking smoking with cardiovascular and metabolic diseases. Among the effects of smoking there is the alteration of lipid metabolism through the increase in lipolysis, insulin resistance and tissue lipotoxicity. Smoking is both prothrombotic and atherogenic. As an effect, the risk of acute myocardial infarction, sudden cardiac death, stroke, aortic aneurysm and peripheral vascular disease is increased. Even very low doses of exposure increase the risk of cardiovascular disease (CVD) and metabolic alterations. On the other hand, smoking cessation restores, at least in part, lipid metabolism and the benefits can be observed already after a short period of abstinence from smoking, although it occurs several years before the risks approach those of the never-smoker.
Keywords: Insulin resistance, lipolysi, tobacco smoking, nicotine
Current Pharmaceutical Design
Title: Impact of Tobacco Smoking on Lipid Metabolism, Body Weight and Cardiometabolic Risk
Volume: 16 Issue: 23
Author(s): Amalia Gastaldelli, Franco Folli and Silvia Maffei
Affiliation:
Keywords: Insulin resistance, lipolysi, tobacco smoking, nicotine
Abstract: Tobacco smoking is the most important preventable cause of cardiovascular disease. In this paper we review current epidemiological and pathophysiological evidence linking smoking with cardiovascular and metabolic diseases. Among the effects of smoking there is the alteration of lipid metabolism through the increase in lipolysis, insulin resistance and tissue lipotoxicity. Smoking is both prothrombotic and atherogenic. As an effect, the risk of acute myocardial infarction, sudden cardiac death, stroke, aortic aneurysm and peripheral vascular disease is increased. Even very low doses of exposure increase the risk of cardiovascular disease (CVD) and metabolic alterations. On the other hand, smoking cessation restores, at least in part, lipid metabolism and the benefits can be observed already after a short period of abstinence from smoking, although it occurs several years before the risks approach those of the never-smoker.
Export Options
About this article
Cite this article as:
Gastaldelli Amalia, Folli Franco and Maffei Silvia, Impact of Tobacco Smoking on Lipid Metabolism, Body Weight and Cardiometabolic Risk, Current Pharmaceutical Design 2010; 16 (23) . https://dx.doi.org/10.2174/138161210792062858
DOI https://dx.doi.org/10.2174/138161210792062858 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacophore and 3D QSAR Study of TGFβ Inhibitors
Letters in Drug Design & Discovery The Urokinase-type Plasminogen Activator and the Generation of Inhibitors of Urokinase Activity and Signaling
Current Pharmaceutical Design Protective Role of Diabetes Mellitus on Abdominal Aortic Aneurysm Pathogenesis: Myth or Reality?
Current Vascular Pharmacology Triglycerides and Vascular Risk: Insights from Epidemiological Data and Interventional Studies
Current Drug Targets Modulation of Angiotensin II Effects, A Potential Novel Approach to Inflammatory and Immune Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Dye Visualization - A Method for Investigating Biomechanical Flows
Current Pharmaceutical Biotechnology Meet Our Editorial Board Member
Current Vascular Pharmacology Molecular Genetics of Abdominal Aortic Aneurysm: Therapeutic Implications
Current Pharmacogenomics and Personalized Medicine Taking Risk Prediction to the Next Level. Advances in Biomarker Research for Atherosclerosis
Current Pharmaceutical Design The Effects of Olprinone, a Phosphodiesterase 3 Inhibitor, on Systemic and Cerebral Circulation
Current Vascular Pharmacology Therapeutic Hypothermia as a Neuroprotective Strategy in Neonatal Hypoxic-Ischemic Brain Injury and Traumatic Brain Injury
Current Molecular Medicine Non-coding RNAs and Hypertension–Unveiling Unexpected Mechanisms of Hypertension by the Dark Matter of the Genome
Current Hypertension Reviews Novel Therapeutic Approaches Targeting Matrix Metalloproteinases in Cardiovascular Disease
Current Topics in Medicinal Chemistry Artery of Percheron Infarction: A Characteristic Pattern of Ischemia and Variable Clinical Presentation: A Literature Review
Current Medical Imaging Pediatric Chronic Daily Headache
Current Pediatric Reviews Template-Mediated Biomineralization for Bone Tissue Engineering
Current Stem Cell Research & Therapy Immunosuppressive Treatments in Acute Myocardial Infarction and Stroke
Current Pharmaceutical Biotechnology Drug Eluting Stents for Vulnerable Plague
Current Pharmaceutical Design Haptoglobin Polymorphisms and Fucosylation Change: Possible Influence of Variation on the Identified Lung Cancer-relevant Biomarkers
Current Proteomics Lipoprotein (a) and Cardiovascular Risk: The Show Must go on
Current Medicinal Chemistry